+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pheochromocytoma Drug"

Pheochromocytoma - Pipeline Insight, 2024 - Product Thumbnail Image

Pheochromocytoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 40 Pages
  • Global
From
Pheochromocytoma Global Market Report 2024 - Product Thumbnail Image

Pheochromocytoma Global Market Report 2024

  • Report
  • January 2024
  • 175 Pages
  • Global
From
From
Pheochromocytoma - Epidemiology Forecast to 2032 - Product Thumbnail Image

Pheochromocytoma - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Pheochromocytoma - Pipeline Review, H2 2020 - Product Thumbnail Image

Pheochromocytoma - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 161 Pages
  • Global
From
  • 6 Results (Page 1 of 1)
Loading Indicator

Pheochromocytoma is a rare type of tumor that develops in the adrenal glands and is associated with the production of hormones that can cause high blood pressure. Treatment for pheochromocytoma typically involves surgery to remove the tumor, as well as medications to control the symptoms. Oncology drugs used to treat pheochromocytoma include alpha-blockers, beta-blockers, and calcium channel blockers. These drugs are used to reduce the production of hormones and to control the symptoms associated with the tumor. In some cases, chemotherapy may also be used to treat the tumor. The pheochromocytoma drug market is a niche market within the larger oncology drug market. It is composed of a variety of pharmaceutical companies that specialize in the development and manufacture of drugs to treat pheochromocytoma. Some of the major players in this market include Novartis, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more